These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Advances in radioimmunotherapy in the age of molecular engineering and pretargeting. Sharkey RM; Goldenberg DM Cancer Invest; 2006 Feb; 24(1):82-97. PubMed ID: 16466997 [TBL] [Abstract][Full Text] [Related]
27. [Radioimmunotherapy: current state of the problem]. Chernov VI; Bragina OD; Sinilkin IG; Medvedeva AA; Zelchan RV Vopr Onkol; 2016; 62(1):24-30. PubMed ID: 30444328 [TBL] [Abstract][Full Text] [Related]
34. The evolution of the discipline of vascular biology: from systems physiology to molecular biology to molecular systems. Loscalzo J Circ Res; 2003 Oct; 93(7):583-5. PubMed ID: 14525918 [No Abstract] [Full Text] [Related]
35. Radioimmunotherapy is an effective adjuvant treatment after cytoreductive surgery of experimental colonic peritoneal carcinomatosis. Koppe MJ; Hendriks T; Boerman OC; Oyen WJ; Bleichrodt RP J Nucl Med; 2006 Nov; 47(11):1867-74. PubMed ID: 17079821 [TBL] [Abstract][Full Text] [Related]
38. [Research prospects in the field of molecular bases of developmental biology]. Astaurov BL Ontogenez; 1989; 20(6):567-76. PubMed ID: 2616108 [No Abstract] [Full Text] [Related]
39. Radioimmunotherapy with alpha-particle emitting radionuclides. Zalutsky MR; Pozzi OR Q J Nucl Med Mol Imaging; 2004 Dec; 48(4):289-96. PubMed ID: 15640792 [TBL] [Abstract][Full Text] [Related]
40. Potential and pitfalls of therapy with alpha-particles. Welch MJ J Nucl Med; 2005 Aug; 46(8):1254-5. PubMed ID: 16085579 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]